
5-Year Clarity AD Data Show Sustained Clinical Benefit With Lecanemab in Early Alzheimer Disease
Key Takeaways
- Clarity AD randomized 1795 early AD patients to lecanemab 10 mg/kg IV q2w versus placebo for 18 months, then 95% of completers entered an extension permitting ongoing active therapy.
- Increasing CDR-SB differences versus ADNI/BioFINDER through years 3–5 (up to −2.05 and −2.54, respectively) suggested durable slowing versus expected natural history decline.
5-year findings from the Clarity AD long-term extension, presented at CTAD 2026, showed progressively greater differences in CDR-SB outcomes compared with external natural history cohorts.
Continuous treatment with lecanemab-irmb (Leqembi; Eisai/Biogen) was associated with sustained clinical benefit over 5 years in patients with early Alzheimer disease (AD). Findings from the phase 3 Clarity AD trial (NCT03887455) long term extension (LTE), presented at the
The Clarity AD trial originally enrolled 1795 patients with early AD, including those with mild cognitive impairment (MCI) due to AD or mild AD dementia. Investigators, led by Christopher van Dyck, MD, director of the Alzheimer's Disease Research Unit, Yale Alzheimer's Disease Research Center, and the Division of Aging and Geriatric Psychiatry at Yale School of Medicine, randomly assigned participants to receive either lecanemab 10 mg/kg intravenously every 2 weeks (n = 898) or placebo (n = 897) during the 18-month, double-blind, placebo-controlled core study.1
Following completion of the core study, 95% of completing participants elected to enter the LTE, during which patients could receive continued lecanemab treatment. Among those enrolled, 351 patients received 5 years of continuous treatment. The findings also showed that a majority of patients with low baseline tau accumulation experienced improvement or no decline across several clinical measures after 5 years of treatment.1
5-year clinical outcomes compared with natural history cohorts
Among patients who received continuous lecanemab treatment through 5 years, investigators assessed changes in CDR-SB scores against disease progression observed in two external natural history cohorts: the Alzheimer’s Disease Neuroimaging Initiative (ADNI) and BioFINDER. CDR-SB evaluates cognitive and functional impairment across six domains, with higher scores reflecting greater disease severity.1
Compared with ADNI, the difference in mean CDR-SB change from baseline between the continuously treated lecanemab group and the natural history cohort was −1.00 points at year 3, −1.78 points at year 4, and −2.05 points at year 5. Comparisons with BioFINDER showed differences of −1.42, −2.24, and −2.54 points at the respective time points. In both comparisons, the differences between groups increased over time.
Investigators also evaluated disease-stage progression using CDR-SB thresholds. Relative to ADNI, continuous lecanemab treatment was associated with a 36% reduction in the relative risk of progressing to the next disease stage over 5 years. By year 5, 61.9% of lecanemab-treated patients had progressed from MCI to mild AD dementia or from mild AD dementia to moderate AD dementia, compared with 77.5% of individuals in ADNI.
When assessing progression to moderate or severe AD dementia, the relative risk reduction compared with ADNI was 49%. In the lecanemab group, 31% of patients progressed to moderate or severe dementia, compared with 48.7% in the natural history cohort. ADNI and BioFINDER were not concurrent randomized control groups in the 5-year analysis, and differences in patient characteristics and study methodologies may influence comparisons.
Outcomes among patients with low baseline tau
Additional analyses examined clinical outcomes among patients with low tau accumulation at baseline. Clarity AD included an optional tau positron emission tomography (PET) substudy to characterize baseline tau burden and assess whether treatment outcomes differed according to disease stage.1
At 5 years, 66% of patients in the low-tau subgroup demonstrated no decline or improvement on CDR-SB, including 62% that showed improvement on the measure. Similar patterns were observed across cognitive and functional assessments.
On the Alzheimer's Disease Assessment Scale–Cognitive Subscale 14 (ADAS-Cog14), 55% of patients demonstrated no decline or improvement, including 52% who showed improvement. On the Alzheimer's Disease Cooperative Study–Activities of Daily Living Scale for MCI (ADCS MCI-ADL), 69% demonstrated no decline or improvement, with 62% showing improvement.
Together, these findings suggest that patients who begin treatment with lower baseline tau burden may experience sustained clinical benefit over extended treatment. However, the subgroup findings do not establish that baseline tau independently predicts treatment response, and the reported proportions should be interpreted within the context of the LTE population and its follow-up.
Safety findings and additional Context
The 5-year safety analysis did not identify any new safety findings with continued lecanemab treatment. Amyloid-related imaging abnormalities with edema or effusion (ARIA-E) occurred most frequently during the first 6 months of treatment, with incidence generally declining across subsequent 12-month treatment intervals.
ARIA-E incidence was 13.5% during the first 12 months of treatment, followed by 3.6% in the second year, 1.1% in the third year, 1.3% in the fourth year, and 0.6% in the fifth year. For comparison, ARIA-E occurred in 1.7% of patients receiving placebo during the 18-month core study. The findings add to the growing body of long-term clinical and biomarker evidence supporting lecanemab's effects in early AD.
These findings build on
The newly presented 5-year findings extend that work by providing additional clinical outcome data during prolonged treatment, including comparisons with external natural history cohorts and outcomes among patients with lower baseline tau burden. Although the findings offer further insight into the durability of lecanemab treatment, longer-term controlled data will remain important for establishing the magnitude and persistence of clinical benefit.
REFERENCES
1. New 5-year lecanemab data from Clarity AD study long-term extension presented at CTAD 2026. Eisai and Biogen. News release. November 16, 2026. Accessed November 18, 2026. https://investors.biogen.com/news-releases/news-release-details/new-five-year-lecanemab-data-clarity-ad-study-long-term
2. New Data Presented at CTAD 2025 Confirms Pharmacological Effect of LEQEMBI® (lecanemab-irmb) on Neurotoxic Aβ Protofibrils in CSF. News release. Eisai. December 2, 2025. Accessed December 3, 2025. https://www.eisai.com/news/2025/news202584.html
Related to this article








